The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Utilizing combination therapies for multiple myeloma
There are several different types of immunotherapy and associated conjunctional therapies currently being studied that have shown some degree of efficacy for the treatment of multiple myeloma (MM). Speaking from the Myeloma 2017 meeting held in Edinburgh, UK, David Avigan, MD, of the Beth Israel Deaconess Medical Center, Boston, MA, gives an overview of these therapies, including CAR T-cells and dendritic cell vaccines. Dr Avigan explains that whilst these therapies are spearheading an exciting future of MM treatment, there is still a need to develop our understanding of the immune system, and the durability and side effects of these treatments, so that they can be used in the most efficacious combinations and regimens possible.
